Your browser doesn't support javascript.
loading
Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study.
Li, Jing; Bao, Li; Xia, Zhongjun; Wang, Sili; Zhou, Xin; Ding, Kaiyang; Zhang, Wenhao; Yang, Wei; Li, Bingzong; Fu, Chengcheng; Chen, Bing; Hua, Luoming; Wang, Liang; Luo, Jun; Yang, Yang; Xu, Tianhong; Wang, Weida; Huang, Yun; Wu, Guolin; Liu, Peng.
Afiliação
  • Li J; Department of Hematology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, People's Republic of China.
  • Bao L; Department of Hematology, Beijing Jishuitan Hospital, Beijing, China.
  • Xia Z; Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Wang S; The First Affiliated Hospital of Xiamen University, Xiamen, China.
  • Zhou X; Wuxi People Hospital, WuXi, China.
  • Ding K; Anhui Provincial Cancer Hospital, Hefei, China.
  • Zhang W; Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China.
  • Yang W; Shengjing Hospital of China Medical University, Shengjing, China.
  • Li B; The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
  • Fu C; Department of Hematology, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, China.
  • Chen B; Department of Hematology, The Affiliated Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, China.
  • Hua L; The Affiliated Hospital of Hebei University, Baoding, China.
  • Wang L; Department of Hematology, ZhuJiang Hospital of Southern Medical Univeristy, Guangzhou, China.
  • Luo J; The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
  • Yang Y; Department of Hematology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, People's Republic of China.
  • Xu T; Department of Hematology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, People's Republic of China.
  • Wang W; Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Huang Y; The First Affiliated Hospital of Xiamen University, Xiamen, China.
  • Wu G; Anhui Provincial Cancer Hospital, Hefei, China.
  • Liu P; Department of Hematology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, People's Republic of China. liu.peng@zs-hospital.sh.cn.
Ann Hematol ; 99(11): 2589-2598, 2020 Nov.
Article em En | MEDLINE | ID: mdl-32892275
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Compostos de Boro / Protocolos de Quimioterapia Combinada Antineoplásica / Doenças do Sistema Nervoso Periférico / Glicina / Mieloma Múltiplo Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Compostos de Boro / Protocolos de Quimioterapia Combinada Antineoplásica / Doenças do Sistema Nervoso Periférico / Glicina / Mieloma Múltiplo Idioma: En Ano de publicação: 2020 Tipo de documento: Article